Common data elements for preclinical epilepsy research: Standards for data collection and reporting. A TASK3 report of the AES/ILAE Translational Task Force of the ILAE
- PMID: 29105074
- PMCID: PMC5679401
- DOI: 10.1111/epi.13906
Common data elements for preclinical epilepsy research: Standards for data collection and reporting. A TASK3 report of the AES/ILAE Translational Task Force of the ILAE
Abstract
The major objective of preclinical translational epilepsy research is to advance laboratory findings toward clinical application by testing potential treatments in animal models of seizures and epilepsy. Recently there has been a focus on the failure of preclinical discoveries to translate reliably, or even to be reproduced in different laboratories. One potential cause is a lack of standardization in preclinical data collection. The resulting difficulties in comparing data across studies have led to high cost and missed opportunity, which in turn impede clinical trials and advances in medical care. Preclinical epilepsy research has successfully brought numerous antiseizure treatments into the clinical practice, yet the unmet clinical needs have prompted the reconsideration of research strategies to optimize epilepsy therapy development. In the field of clinical epilepsy there have been successful steps to improve such problems, such as generation of common data elements (CDEs) and case report forms (CRFs and standards of data collection and reporting) by a team of leaders in the field. Therefore, the Translational Task Force was appointed by the International League Against Epilepsy (ILAE) and the American Epilepsy Society (AES), in partnership with the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institutes of Health (NIH) to define CDEs for animal epilepsy research studies and prepare guidelines for data collection and experimental procedures. If adopted, the preclinical CDEs could facilitate collaborative epilepsy research, comparisons of data across different laboratories, and promote rigor, transparency, and impact, particularly in therapy development.
Keywords: Common data elements; Epilepsy; Guidelines; Preclinical; Standardization.
Wiley Periodicals, Inc. © 2017 International League Against Epilepsy.
Conflict of interest statement
This report was written by experts selected by the International League Against Epilepsy (ILAE) and the American Epilepsy Society (AES) and was approved for publication by the ILAE and the AES. Opinions expressed by the authors, however, do not necessarily represent the policy or position of the ILAE or the AES.
Lauren Harte-Hargrove: none; Jacqueline French: J. French receives New York University (NYU) salary support from the Epilepsy Foundation and for consulting work on behalf of the Epilepsy Study Consortium for Acorda, Adamas, Alexza, Anavex, Axcella Health, Biogen, BioPharm Solutions, Cerecor, Concert Pharmaceuticals, Engage, Eisai, Glaxo Smith-Kline, GW Pharma, Marinus, Nestle-Health Science, Neurelis, Novartis, Pfizer, Pfizer-Neusentis, Ovid, Sage, SK Life Sciences, Sunovion, Takeda, UCB Inc., Upsher Smith, Xenon Pharmaceuticals, Zogenix and Zynerba. J. French has also received research grants from Acorda, Alexza, Eisai Medical Research, Lewis County General Hospital (LCGH), Lundbeck, Pfizer, SK Life Sciences, Sunovion, UCB Inc., Upsher-Smith and Vertex, as well as grants from the Epilepsy Research Foundation, Epilepsy Study Consortium, Epilepsy Therapy Project, and NINDS. She is on the editorial board of Lancet Neurology, Neurology Today and Epileptic disorders. She is scientific officer for the Epilepsy Foundation for which NYU receives salary support. She has received travel reimbursement related to research, advisory meetings, or presentation of results at scientific meetings from the Epilepsy Study Consortium, the Epilepsy Foundation, Eisai, GW Pharma, Marinus, Nestle Life Sciences, Pfizer, Sage, SK life Sciences, Takeda, UCB Inc., Upsher-Smith, Zogenix, Zynerba; Asla Pitkanen: none; A. Galanopoulou is co-Editor in Chief of Epilepsia Open; Vicky Whittemore: none; Helen Scharfman: H. Scharfman is a member of the Scientific Board of Advisors for Pyramid Biosciences.
A. Pitkanen, A. Galanopoulou, J. French, L. Harte-Hargrove and H. Scharfman have received travel reimbursement from the ILAE, AES, and NINDS for meetings pertaining to these CDEs.
Figures
References
-
- Galanopoulou AS, Simonato M, French JA, et al. Joint AES/ILAE translational workshop to optimize preclinical epilepsy research. Epilepsia. 2013;54(Suppl 4):1–2. - PubMed
-
- National Institute of Neurological Disorders and Stroke. [Accessed October 18, 2016];NINDS Common Data Elements. 2016 Available at: https://commondataelements.ninds.nih.gov.
-
- National Institutes of Health. [Accessed October 18, 2016];NIH Common Data Element (CDE) Resource Portal. 2013 Available at: https://www.nlm.nih.gov/cde/glossary.html#cdedefinition.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical